These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38565383)

  • 1. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Suppresses macrophage capping protein beyond STING activation.
    Xiao Z; Cui X; Liu F; Wang Y; Liu X; Zhou W; Zhang Y
    Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167149. PubMed ID: 38565383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
    Downey CM; Aghaei M; Schwendener RA; Jirik FR
    PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Conlon J; Burdette DL; Sharma S; Bhat N; Thompson M; Jiang Z; Rathinam VA; Monks B; Jin T; Xiao TS; Vogel SN; Vance RE; Fitzgerald KA
    J Immunol; 2013 May; 190(10):5216-25. PubMed ID: 23585680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
    J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA.
    Chang J; Hou S; Yan X; Li W; Xiao J
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA.
    Shih AY; Damm-Ganamet KL; Mirzadegan T
    Biophys J; 2018 Jan; 114(1):32-39. PubMed ID: 29320694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential.
    Prantner D; Perkins DJ; Lai W; Williams MS; Sharma S; Fitzgerald KA; Vogel SN
    J Biol Chem; 2012 Nov; 287(47):39776-88. PubMed ID: 23027866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach.
    Pan ST; Zhou ZW; He ZX; Zhang X; Yang T; Yang YX; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():937-68. PubMed ID: 25733813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation.
    Temizoz B; Shibahara T; Hioki K; Hayashi T; Kobiyama K; Lee MSJ; Surucu N; Sag E; Kumanogoh A; Yamamoto M; Gursel M; Ozen S; Kuroda E; Coban C; Ishii KJ
    Front Immunol; 2024; 15():1353336. PubMed ID: 38533502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA.
    Gao P; Zillinger T; Wang W; Ascano M; Dai P; Hartmann G; Tuschl T; Deng L; Barchet W; Patel DJ
    Cell Rep; 2014 Sep; 8(6):1668-1676. PubMed ID: 25199835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular disrupting agent drug classes differ in effects on the cytoskeleton.
    Kim S; Peshkin L; Mitchison TJ
    PLoS One; 2012; 7(7):e40177. PubMed ID: 22848372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of C7-functionalized DMXAA derivatives as potential human-STING agonists.
    Hwang J; Kang T; Lee J; Choi BS; Han S
    Org Biomol Chem; 2019 Feb; 17(7):1869-1874. PubMed ID: 30117503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z; Baguley BC; Ching LM
    Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview on Vadimezan (DMXAA): The vascular disrupting agent.
    Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Samandari-Rad S; Zarghami N
    Chem Biol Drug Des; 2018 May; 91(5):996-1006. PubMed ID: 29288534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase.
    Zhang SH; Zhang Y; Shen J; Zhang S; Chen L; Gu J; Mruk JS; Cheng G; Zhu L; Kunapuli SP; Ding Z
    J Thromb Haemost; 2013 Oct; 11(10):1855-66. PubMed ID: 23902231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative Strategy for Investigating the Interactions between STING and Small-Molecule Ligands.
    Xu Y; Li W; Zhou X; Gao Y; Ding L; Xu L; Mao X; Zhou A; Wang X; Ning X
    Langmuir; 2022 Nov; 38(46):14185-14191. PubMed ID: 36354159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Invest New Drugs; 2002 Aug; 20(3):281-95. PubMed ID: 12201491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Roberts ZJ; Ching LM; Vogel SN
    J Interferon Cytokine Res; 2008 Mar; 28(3):133-9. PubMed ID: 18338946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.